Logistics outsourcing company D. Logistics of Germany announced an agreement with Siemens Medical Engineering Group to start a new e-business venture in Europe’s medical market. Siemens will hold a 51% stake in the new company.The new company will
Logistics outsourcing company D. Logistics of Germany announced an agreement with Siemens Medical Engineering Group to start a new e-business venture in Europes medical market. Siemens will hold a 51% stake in the new company.
The new company will be aimed at establishing an electronic business communications platform for e-business between suppliers and customers in medical markets.
Using the new platform, hospitals, private medical practices, and pharmacies will be able to communicate via network channels with suppliers of their choice to speed orders for materials and medicines.
Siemens as a whole expects to soon be generating more than 25% of its total sales with e-business activity.
In addition to outsourcing optimizing logistics, D. Logistics sells B2B customers consulting services, temporary help, and tailored information technology. The company has 1200 employees and is headquartered in Leverkusen, Germany.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.